|Bid||8.40 x 900|
|Ask||39.80 x 800|
|Day's Range||8.83 - 9.31|
|52 Week Range||6.30 - 14.50|
|Beta (3Y Monthly)||1.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 26, 2017 - May 1, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.00|
If you want to know who really controls MediciNova, Inc. (NASDAQ:MNOV), then you'll have to look at the makeup of its share registry. Insiders often own a large chunk of Read More...
LA JOLLA, Calif., Dec. 12, 2018 -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock.
In August 2018, MediciNova, Inc. (MNOV) announced plans to conduct a Phase 2/3 trial of MN-166 in degenerative cervical myelopathy (DCM) through an agreement with the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust. The Principal Investigator is Dr. Mark Kotter and the trial is being funded by a grant from the National Institute for Health Research (NIHR) in the United Kingdom. MediciNova is not funding the trial but will provide the study drug supply, regulatory support, and safety monitoring support.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 3) Amarin Corporation plc (NASDAQ: AMRN ) BIOLINERX Ltd/S ...
LA JOLLA, Calif., Oct. 04, 2018 -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock.
On September 25, 2018, MediciNova, Inc. (MNOV) announced that the FDA provided positive feedback in regards to the company’s development plan for MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS). The FDA did not raise any concerns with the safety of MN-166, only a single trial may be necessary if there is a statistically significant result when comparing MN-166 to placebo in a functional outcome (such as ALSFRS-R), and the agency would like to see a broad range of ALS patients with randomization stratified by baseline disease severity.
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received positive feedback from the FDA (U.S. Food and Drug Administration) regarding MediciNova’s Phase 3 clinical development plan for MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS). If a single trial shows that MN-166 (ibudilast) has a statistically significant benefit compared to placebo in a measure of functional activity, such as ALSFRS-R, an additional trial may not be necessary. In order to detect the maximal potential benefit of MN-166 (ibudilast), FDA encouraged including a broad ALS population, with randomization that is stratified by baseline disease severity.
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 9:30 am at the Sofitel Hotel in New York City. Management will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through Ladenburg Thalmann. MediciNova, Inc. is a publicly-traded biopharmaceutical company founded on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with high unmet medical needs with a primary commercial focus on the U.S. market.
On July 23, 2018, MediciNova, Inc. (MNOV) filed form 10-Q with financial results for the second quarter of 2018. As expected, the company did not report any revenues. The increase in R&D expenses was primarily due to increased clinical trial costs for MN-166.
This group was comprised of 31 subjects out of a total of 49 subjects in the full analysis set. A second subgroup comprised of 39 subjects (out of a total of 67 subjects in the full analysis set) who had either bulbar onset or upper limb onset ALS with or without NIV (the “Early ALS + NIV subgroup”). The score is utilized to keep track of the health of all ALS patients, and is a common outcome measure in ALS clinical trials.
MediciNova Inc’s (NASDAQ:MNOV): MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in theRead More...
After reading MediciNova Inc’s (NASDAQ:MNOV) most recent earnings announcement (31 March 2018), I found it useful to look back at how the company has performed in the past and compareRead More...